
Opinion|Videos|September 16, 2024
BTK Inhibitor-Associated Adverse Events
The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Ferric Maltol to Adolescents, Addressing a Critical Gap in Iron Deficiency Care
2
Occupational Factors Can Increase Risk of Long COVID
3
T-DXd Granted Breakthrough Therapy Designation in Post-Neoadjuvant HER2-Positive Early Breast Cancer
4
Reading Between the Codes: How Seemingly Unrelated Conditions May Signal Earlier Multiple Myeloma
5
































































































































































































